Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage
Recommended Citation
Kasetty VM, Starnes DC, Sood N, Qin LG, Moses MM, Frazier HK, Singh H, and Marcus DM. Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage. Ophthalmic Surg Lasers Imaging Retina 2023; 54(2):89-96.
Document Type
Article
Publication Date
2-1-2023
Publication Title
Ophthalmic Surg Lasers Imaging Retina
Abstract
BACKGROUND AND OBJECTIVE: To report the 3-year outcomes for endolaserless vitrectomy with intravitreal aflibercept injection (IAI) monotherapy for proliferative diabetic retinopathy (PDR)-related vitreous hemorrhage (VH).
MATERIALS AND METHOD: Eyes underwent endolaserless vitrectomy and received one preoperative and intraoperative IAI followed by randomization to a q8week or q16week IAI group. Additional IAI was administered as needed.
RESULTS: 31/40 eyes were randomized (14 q8week eyes, 17 q16week eyes). Through 152 weeks, q8week and q16week eyes received 18.6 and 12.1 IAI, respectively. Q8week eyes observed a 34 letter visual acuity (VA) increase (P = 0.003) compared to a 27 letter increase in the q16week group (P = 0.013).
CONCLUSIONS: Endolaserless vitrectomy with aflibercept monotherapy for PDR-related VH provides significant long-term visual gains. Frequent IAI is required for fewer proliferative consequences.
Medical Subject Headings
Humans; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetes Mellitus; Diabetic Retinopathy; Intravitreal Injections; Vascular Endothelial Growth Factor A; Vitrectomy; Vitreous Hemorrhage
PubMed ID
36780633
Volume
54
Issue
2
First Page
89
Last Page
96
